 | |
| Clinical data | |
|---|---|
| Trade names | Conflictan |
| Other names | CERM-1766 |
|
Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| CompTox Dashboard ( EPA) | |
| ECHA InfoCard | 100.043.490 |
| Chemical and physical data | |
| Formula | C14H18F3NO |
| Molar mass | 273.299 g·mol−1 |
| 3D model ( JSmol) | |
| |
Oxaflozane ( INN) (brand name Conflictan) is an antidepressant and anxiolytic drug that was introduced by Solvay in France in 1982 for the treatment of depression but has since been discontinued. [1] [2] [3] [4] It is a prodrug of flumexadol (N-dealkyloxaflozane; 2-(3-trifluoromethylphenyl)morpholine; CERM-1841 or 1841-CERM), which is reported to act as an agonist of the serotonin 5-HT1A (pKi = 7.1) and 5-HT2C (pKi = 7.5) receptors and, to a much lesser extent, of the 5-HT2A (pKi = 6.0) receptor. [4] [5] In addition to its serotonergic properties, oxaflozane may also produce anticholinergic side effects at high doses, namely in overdose. [6]
See also
References
- ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 909–. ISBN 978-1-4757-2085-3.
- ^ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. p. 766. ISBN 3-88763-075-0.
- ^ Sittig M (1988). Pharmaceutical Manufacturing Encyclopedia. Park Ridge, N.J., U.S.A: Noyes Publications. p. 1122. ISBN 0-8155-1144-2.
- ^ a b Bégué JP, Bonnet-Delpon D (2 June 2008). "Drugs for CNS Disorders". Bioorganic and Medicinal Chemistry of Fluorine. John Wiley & Sons. pp. 303–. ISBN 978-0-470-28187-1.
- ^ Leysen DC (February 1999). "Selective 5-HT2C agonists as potential antidepressants". IDrugs. 2 (2): 109–20. PMID 16160946.
- ^ Dutertre JP, Barbier P, Suc AL, Jonville AP, Autret E (1992). "Oxaflozane overdose in a child". Journal of Toxicology. Clinical Toxicology. 30 (1): 123–6. doi: 10.3109/15563659208994452. PMID 1542141.
Further reading
- Rascol A, Maurel H, David J, Layani M (1974). "[Preliminary clinical results of a new non tricyclic antidepressive drug: oxaflozane]". Thérapie (in French). 29 (1): 95–9. PMID 4603757.
- Hache J, Duchene-Marullaz P, Streichenberger G (1974). "[Pharmacological profile of a new non tricyclic antidepressant: oxaflozane (1,766 Cerm)]". Thérapie (in French). 29 (1): 81–93. PMID 4849381.
- Constantin M, Pognat JF (1979). "Comparative study of oxaflozane urinary metabolism in man, the dog and the rat. Identification of the principal metabolites". Arzneimittel-Forschung. 29 (1): 109–14. PMID 582104.
- Bertolino A, palermo M, Porro V (1985). "Un nouvel antidépresseur non tricyclique, l'oxaflozane, dans le traitement des syndromes anxio-dépressifs" [Oxaflozane, a new nontricyclic antidepressant in the treatment of anxiety-depressions syndromes]. Acta Therapeutica. 11 (2): 209–218.
- Aguglia E (1986). "On the therapetic value of oxaflozane: Its application in the treatment of emotional disturbances of the anxious-depressive type accompanied by somatic manifestations". Acta Therapeutica. 12 (3): 259–268.
 | This article about an anxiolytic is a stub. You can help Wikipedia by expanding it. |
|
| |
| Clinical data | |
|---|---|
| Trade names | Conflictan |
| Other names | CERM-1766 |
|
Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| CompTox Dashboard ( EPA) | |
| ECHA InfoCard | 100.043.490 |
| Chemical and physical data | |
| Formula | C14H18F3NO |
| Molar mass | 273.299 g·mol−1 |
| 3D model ( JSmol) | |
| |
Oxaflozane ( INN) (brand name Conflictan) is an antidepressant and anxiolytic drug that was introduced by Solvay in France in 1982 for the treatment of depression but has since been discontinued. [1] [2] [3] [4] It is a prodrug of flumexadol (N-dealkyloxaflozane; 2-(3-trifluoromethylphenyl)morpholine; CERM-1841 or 1841-CERM), which is reported to act as an agonist of the serotonin 5-HT1A (pKi = 7.1) and 5-HT2C (pKi = 7.5) receptors and, to a much lesser extent, of the 5-HT2A (pKi = 6.0) receptor. [4] [5] In addition to its serotonergic properties, oxaflozane may also produce anticholinergic side effects at high doses, namely in overdose. [6]
See also
References
- ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 909–. ISBN 978-1-4757-2085-3.
- ^ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. p. 766. ISBN 3-88763-075-0.
- ^ Sittig M (1988). Pharmaceutical Manufacturing Encyclopedia. Park Ridge, N.J., U.S.A: Noyes Publications. p. 1122. ISBN 0-8155-1144-2.
- ^ a b Bégué JP, Bonnet-Delpon D (2 June 2008). "Drugs for CNS Disorders". Bioorganic and Medicinal Chemistry of Fluorine. John Wiley & Sons. pp. 303–. ISBN 978-0-470-28187-1.
- ^ Leysen DC (February 1999). "Selective 5-HT2C agonists as potential antidepressants". IDrugs. 2 (2): 109–20. PMID 16160946.
- ^ Dutertre JP, Barbier P, Suc AL, Jonville AP, Autret E (1992). "Oxaflozane overdose in a child". Journal of Toxicology. Clinical Toxicology. 30 (1): 123–6. doi: 10.3109/15563659208994452. PMID 1542141.
Further reading
- Rascol A, Maurel H, David J, Layani M (1974). "[Preliminary clinical results of a new non tricyclic antidepressive drug: oxaflozane]". Thérapie (in French). 29 (1): 95–9. PMID 4603757.
- Hache J, Duchene-Marullaz P, Streichenberger G (1974). "[Pharmacological profile of a new non tricyclic antidepressant: oxaflozane (1,766 Cerm)]". Thérapie (in French). 29 (1): 81–93. PMID 4849381.
- Constantin M, Pognat JF (1979). "Comparative study of oxaflozane urinary metabolism in man, the dog and the rat. Identification of the principal metabolites". Arzneimittel-Forschung. 29 (1): 109–14. PMID 582104.
- Bertolino A, palermo M, Porro V (1985). "Un nouvel antidépresseur non tricyclique, l'oxaflozane, dans le traitement des syndromes anxio-dépressifs" [Oxaflozane, a new nontricyclic antidepressant in the treatment of anxiety-depressions syndromes]. Acta Therapeutica. 11 (2): 209–218.
- Aguglia E (1986). "On the therapetic value of oxaflozane: Its application in the treatment of emotional disturbances of the anxious-depressive type accompanied by somatic manifestations". Acta Therapeutica. 12 (3): 259–268.
|
| This article about an anxiolytic is a stub. You can help Wikipedia by expanding it. |